Across TCGA pan-cancer cohorts, RN7SL453P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RN7SL453P data layer compared with 5 for mass-spec protein.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RN7SL453P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RN7SL453P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
ACC, UCEC, and LUAD are the cancer types where RN7SL453P Mutation most reproducibly stratifies survival.